{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:45:49Z","timestamp":1788493549035,"version":"build-2803163510"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1SF2622N"],"award-info":[{"award-number":["1SF2622N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["12E9716N"],"award-info":[{"award-number":["12E9716N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024253","name":"Western Australian Future Health and Innovation Fund, Government of Western Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014031","name":"Cancerforskningsfonden i Norrland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014031","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006313","name":"Barncancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006313","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cancer Research Institute Ghent"},{"DOI":"10.13039\/501100011851","name":"Kom op tegen Kanker","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-44665-4","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T03:35:07Z","timestamp":1774496107000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Profiling histone post-translational modifications to identify signatures of epigenetic drug response in T-cell acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"16","author":[{"given":"Laura","family":"Corveleyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lien","family":"Provez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman","family":"Satilmis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Refhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Landfors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"Sleeckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Lintermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"De Maesschalck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi S.","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"De Moerloose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Lammens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Deforce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Degerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Goossens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Van Vlierberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Dhaenens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"44665_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nrg3352","volume":"14","author":"HE Wheeler","year":"2013","unstructured":"Wheeler, H. E., Maitland, M. L., Dolan, M. E., Cox, N. J. & Ratain, M. J. Cancer pharmacogenomics: Strategies and challenges. Nat. Rev. Genet. 14, 23\u201334 (2013).","journal-title":"Nat. Rev. Genet."},{"key":"44665_CR2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010617-053021","author":"VM Lauschke","year":"2018","unstructured":"Lauschke, V. M., Barragan, I. & Ingelman-Sundberg, M. Pharmacoepigenetics and toxicoepigenetics: Novel mechanistic insights and therapeutic opportunities. Annu. Rev. Pharmacol. Toxicol. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010617-053021 (2018).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"44665_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/nrg.2016.59","author":"CD Allis","year":"2016","unstructured":"Allis, C. D. & Jenuwein, T. The molecular hallmarks of epigenetic control. Nat. Rev. Genet. https:\/\/doi.org\/10.1038\/nrg.2016.59 (2016).","journal-title":"Nat. Rev. Genet."},{"issue":"293","key":"44665_CR4","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1126\/science.1063127","volume":"1979","author":"T Jenuwein","year":"2001","unstructured":"Jenuwein, T. & Allis, C. D. Translating the histone code. Science 1979(293), 1074\u20131080 (2001).","journal-title":"Science"},{"key":"44665_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1146\/annurev-pharmtox-010617-053021","volume":"58","author":"VM Lauschke","year":"2018","unstructured":"Lauschke, V. M., Barragan, I. & Ingelman-Sundberg, M. Pharmacoepigenetics and toxicoepigenetics: Novel mechanistic insights and therapeutic opportunities. Annu. Rev. Pharmacol. Toxicol. 58, 161\u2013185 (2018).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"44665_CR6","doi-asserted-by":"crossref","unstructured":"Raetz, E. A. & Teachey, D. T. T-cell acute lymphoblastic leukemia. Hematology: the American Society of Hematology Education Program 2016, 580 (2016).","DOI":"10.1182\/asheducation-2016.1.580"},{"key":"44665_CR7","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1182\/blood-2016-07-692608","volume":"129","author":"DI Marks","year":"2017","unstructured":"Marks, D. I. & Rowntree, C. Management of adults with T-cell lymphoblastic leukemia. Blood 129, 1134\u20131142 (2017).","journal-title":"Blood"},{"key":"44665_CR8","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1182\/blood.2023020678","volume":"142","author":"BL Wood","year":"2023","unstructured":"Wood, B. L. et al. Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: A Children\u2019s Oncology Group study. Blood 142, 2069\u20132078 (2023).","journal-title":"Blood"},{"key":"44665_CR9","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.3390\/cancers14174290","volume":"14","author":"T K\u00fcnz","year":"2022","unstructured":"K\u00fcnz, T. et al. Changing landscape in the treatment of adult acute lymphoblastic leukemia (ALL). Cancers 14, 4290 (2022).","journal-title":"Cancers"},{"key":"44665_CR10","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/cas.70010","volume":"116","author":"H Yu","year":"2025","unstructured":"Yu, H. et al. The clinical and molecular characterization of distinct subtypes in adult T Cell acute lymphoblastic leukemia. Cancer Sci. 116, 1126\u20131138 (2025).","journal-title":"Cancer Sci."},{"key":"44665_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma, S. V. et al. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations. Cell 141, 69\u201380 (2010).","journal-title":"Cell"},{"key":"44665_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3390\/cancers10040101","volume":"10","author":"ML Thomas","year":"2018","unstructured":"Thomas, M. L. & Marcato, P. Epigenetic Modifications as Biomarkers of Tumor Development, Therapy Response, and Recurrence across the Cancer Care Continuum. Cancers 10, 101 (2018).","journal-title":"Cancers"},{"key":"44665_CR13","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.1158\/0008-5472.CAN-21-1606","volume":"81","author":"N Wajapeyee","year":"2021","unstructured":"Wajapeyee, N. & Gupta, R. Epigenetic alterations and mechanisms that drive resistance to targeted cancer therapies. Cancer Res. 81, 5589\u20135595 (2021).","journal-title":"Cancer Res."},{"key":"44665_CR14","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1586\/epr.11.47","volume":"8","author":"LM Britton","year":"2011","unstructured":"Britton, L. M., Gonzales-Cope, M., Zee, B. M. & Garcia, B. A. Breaking the histone code with quantitative mass spectrometry. Expert Rev. Proteomics 8, 631\u2013643 (2011).","journal-title":"Expert Rev. Proteomics"},{"key":"44665_CR15","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41597-022-01736-1","volume":"9","author":"L Provez","year":"2022","unstructured":"Provez, L. et al. An interactive mass spectrometry atlas of histone posttranslational modifications in T-cell acute leukemia. Sci. Data 9, 626 (2022).","journal-title":"Sci. Data"},{"key":"44665_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2023.100708","author":"N Demeulemeester","year":"2024","unstructured":"Demeulemeester, N. et al. msqrob2PTM: Differential abundance and differential usage analysis of MS-based proteomics data at the posttranslational modification and peptidoform level. Mol. Cell. Proteomics https:\/\/doi.org\/10.1016\/j.mcpro.2023.100708 (2024).","journal-title":"Mol. Cell. Proteomics"},{"key":"44665_CR17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/hon.2051","volume":"31","author":"S-L Xue","year":"2013","unstructured":"Xue, S.-L. et al. Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: A retrospective study of 25 Chinese patients. Hematol Oncol 31, 206\u2013212 (2013).","journal-title":"Hematol Oncol"},{"key":"44665_CR18","doi-asserted-by":"publisher","first-page":"5327","DOI":"10.1002\/cam4.3079","volume":"9","author":"J-J Qian","year":"2020","unstructured":"Qian, J.-J. et al. CAG regimen for refractory or relapsed adult T-cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study. Cancer Med. 9, 5327\u20135334 (2020).","journal-title":"Cancer Med."},{"key":"44665_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/ajh.21066","volume":"83","author":"S-L Xue","year":"2008","unstructured":"Xue, S.-L., Wu, D.-P., Sun, A.-N. & Tang, X.-W. CAG regimen enables relapsed or refractory T-cell acute lymphocytic leukemia patients to achieve complete remission: A report of six cases. Am. J. Hematol. 83, 167\u2013170 (2008).","journal-title":"Am. J. Hematol."},{"key":"44665_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2921","author":"B Pang","year":"2013","unstructured":"Pang, B. et al. Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat. Commun. https:\/\/doi.org\/10.1038\/ncomms2921 (2013).","journal-title":"Nat. Commun."},{"key":"44665_CR21","doi-asserted-by":"publisher","first-page":"6095","DOI":"10.1111\/febs.15583","volume":"288","author":"SY van der Zanden","year":"2021","unstructured":"van der Zanden, S. Y., Qiao, X. & Neefjes, J. New insights into the activities and toxicities of the old anticancer drug doxorubicin. FEBS J. 288, 6095\u20136111 (2021).","journal-title":"FEBS J."},{"key":"44665_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1811","author":"B Pang","year":"2015","unstructured":"Pang, B., De Jong, J., Qiao, X., Wessels, L. F. A. & Neefjes, J. Chemical profiling of the genome with anti-cancer drugs defines target specificities. Nat. Chem. Biol. https:\/\/doi.org\/10.1038\/nchembio.1811 (2015).","journal-title":"Nat. Chem. Biol."},{"key":"44665_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/leu.2017.282","volume":"32","author":"M Waibel","year":"2018","unstructured":"Waibel, M. et al. Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia. Leukemia 32, 237\u2013241. https:\/\/doi.org\/10.1038\/leu.2017.282 (2018).","journal-title":"Leukemia"},{"key":"44665_CR24","doi-asserted-by":"publisher","first-page":"5093","DOI":"10.1182\/blood-2007-10-117762","volume":"111","author":"A Scuto","year":"2008","unstructured":"Scuto, A. et al. The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood 111, 5093\u20135100 (2008).","journal-title":"Blood"},{"key":"44665_CR25","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/leu.2010.315","volume":"25","author":"H Hasegawa","year":"2011","unstructured":"Hasegawa, H. et al. LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia\/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway. Leukemia 25, 575\u2013587 (2011).","journal-title":"Leukemia"},{"key":"44665_CR26","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1080\/10428194.2017.1361022","volume":"59","author":"M Duvic","year":"2018","unstructured":"Duvic, M. et al. Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. Leuk. Lymphoma 59, 880\u2013887 (2018).","journal-title":"Leuk. Lymphoma"},{"key":"44665_CR27","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.3109\/10428194.2015.1137292","volume":"57","author":"PL Zinzani","year":"2016","unstructured":"Zinzani, P. L. et al. Romidepsin in relapsed\/refractory T-cell lymphomas: Italian experience and results of a named patient program. Leuk. Lymphoma 57, 2370\u20132374 (2016).","journal-title":"Leuk. Lymphoma"},{"key":"44665_CR28","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1158\/1535-7163.MCT-16-0749","volume":"16","author":"MR Makena","year":"2017","unstructured":"Makena, M. R., Koneru, B., Nguyen, T. H., Kang, M. H. & Reynolds, C. P. Reactive oxygen species-mediated synergism of fenretinide and romidepsin in preclinical models of T-cell lymphoid malignancies. Mol. Cancer Ther. 16, 649\u2013661 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"44665_CR29","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/hon.2421","volume":"36","author":"MW Brunvand","year":"2018","unstructured":"Brunvand, M. W. & Carson, J. Complete remission with romidepsin in a patient with T-cell acute lymphoblastic leukemia refractory to induction hyper-CVAD. Hematol. Oncol. 36, 340\u2013343. https:\/\/doi.org\/10.1002\/hon.2421 (2018).","journal-title":"Hematol. Oncol."},{"key":"44665_CR30","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s43018-021-00249-x","volume":"2","author":"MB Pappalardi","year":"2021","unstructured":"Pappalardi, M. B. et al. Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nat Cancer 2, 1002\u20131017 (2021).","journal-title":"Nat Cancer"},{"key":"44665_CR31","doi-asserted-by":"publisher","first-page":"107327482210740","DOI":"10.1177\/10732748221074051","volume":"29","author":"SA Malkaram","year":"2022","unstructured":"Malkaram, S. A. et al. Differential histone posttranslational modifications induced by DNA hypomethylating agents. Cancer Control 29, 10732748221074052 (2022).","journal-title":"Cancer Control"},{"key":"44665_CR32","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.stemcr.2020.11.002","volume":"15","author":"M V\u00f6lker-Albert","year":"2020","unstructured":"V\u00f6lker-Albert, M., Bronkhorst, A., Holdenrieder, S. & Imhof, A. Histone modifications in stem cell development and their clinical implications. Stem Cell Rep. 15, 1196\u20131205 (2020).","journal-title":"Stem Cell Rep."},{"key":"44665_CR33","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809443","author":"P Richter\u2010Pecha\u0144ska","year":"2018","unstructured":"Richter\u2010Pecha\u0144ska, P. et al. PDX models recapitulate the genetic and epigenetic landscape of pediatric T-cell leukemia. EMBO Mol. Med. https:\/\/doi.org\/10.15252\/emmm.201809443 (2018).","journal-title":"EMBO Mol. Med."},{"key":"44665_CR34","doi-asserted-by":"publisher","first-page":"e65373","DOI":"10.1371\/journal.pone.0065373","volume":"8","author":"M Borss\u00e9n","year":"2013","unstructured":"Borss\u00e9n, M. et al. Promoter DNA methylation pattern identifies prognostic subgroups in childhood T-cell acute lymphoblastic leukemia. PLoS One 8, e65373 (2013).","journal-title":"PLoS One"},{"key":"44665_CR35","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1182\/blood.2024026027","volume":"145","author":"F Sch\u00e4fer Hackenhaar","year":"2025","unstructured":"Sch\u00e4fer Hackenhaar, F. et al. CpG island methylator phenotype classification improves risk assessment in pediatric T-cell acute lymphoblastic leukemia. Blood 145, 2161\u20132178 (2025).","journal-title":"Blood"},{"key":"44665_CR36","doi-asserted-by":"publisher","first-page":"654","DOI":"10.3324\/haematol.2016.145391","volume":"101","author":"JPP Meijerink","year":"2016","unstructured":"Meijerink, J. P. P., Cant\u00e9-Barrett, K., Vroegindeweij, E. & Pieters, R. HOXA-activated early T-cell progenitor acute lymphoblastic leukemia: Predictor of poor outcome?. Haematologica 101, 654 (2016).","journal-title":"Haematologica"},{"key":"44665_CR37","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1038\/onc.2011.601","volume":"31","author":"M Rius","year":"2012","unstructured":"Rius, M. & Lyko, F. Epigenetic cancer therapy: Rationales, targets and drugs. Oncogene 31, 4257\u20134265 (2012).","journal-title":"Oncogene"},{"key":"44665_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13148-021-01098-2","volume":"13","author":"T Yang","year":"2021","unstructured":"Yang, T., Yang, Y. & Wang, Y. Predictive biomarkers and potential drug combinations of epi-drugs in cancer therapy. Clin. Epigenetics 13, 1\u201319 (2021).","journal-title":"Clin. Epigenetics"},{"key":"44665_CR39","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1111\/febs.16395","volume":"289","author":"E Skourti","year":"2022","unstructured":"Skourti, E. & Dhillon, P. Cancer epigenetics: Promises and pitfalls for cancer therapy. FEBS J. 289, 1156\u20131159 (2022).","journal-title":"FEBS J."},{"key":"44665_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms2921","volume":"4","author":"B Pang","year":"2013","unstructured":"Pang, B. et al. Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat. Commun. 4, 1\u201313 (2013).","journal-title":"Nat. Commun."},{"key":"44665_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12014-016-9115-z","volume":"13","author":"C Zhang","year":"2016","unstructured":"Zhang, C. et al. Quantitative proteomic analysis of histone modifications in decitabine sensitive and resistant leukemia cell lines. Clin. Proteomics 13, 1\u201311 (2016).","journal-title":"Clin. Proteomics"},{"issue":"12","key":"44665_CR42","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/s43018-023-00645-5","volume":"4","author":"N Liebers","year":"2023","unstructured":"Liebers, N. et al. Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: The prospective non-interventional SMARTrial. Nat. Cancer 4(12), 1648\u20131659 (2023).","journal-title":"Nat. Cancer"},{"key":"44665_CR43","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1158\/2643-3230.BCD-20-0059","volume":"1","author":"J Roels","year":"2020","unstructured":"Roels, J. et al. Aging of preleukemic thymocytes drives CpG island hypermethylation in T-cell acute lymphoblastic leukemia. Blood Cancer Discov. 1, 275\u2013289 (2020).","journal-title":"Blood Cancer Discov."},{"key":"44665_CR44","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1101\/gad.276790.115","volume":"30","author":"A Benyoucef","year":"2016","unstructured":"Benyoucef, A. et al. UTX inhibition as selective epigenetic therapy against TAL1-driven t-cell acute lymphoblastic leukemia. Genes Dev. 30, 508\u2013521 (2016).","journal-title":"Genes Dev."},{"key":"44665_CR45","doi-asserted-by":"publisher","first-page":"3872","DOI":"10.1172\/JCI94645","volume":"128","author":"C Wang","year":"2018","unstructured":"Wang, C. et al. Ezh2 loss propagates hypermethylation at T cell differentiation\u2013regulating genes to promote leukemic transformation. J. Clin. Invest. 128, 3872 (2018).","journal-title":"J. Clin. Invest."},{"key":"44665_CR46","doi-asserted-by":"publisher","first-page":"750789","DOI":"10.3389\/fonc.2021.750789","volume":"11","author":"CF Sin","year":"2021","unstructured":"Sin, C. F. & Man, PheiM. Early T-cell precursor acute lymphoblastic leukemia: Diagnosis, updates in molecular pathogenesis, management, and novel therapies. Front. Oncol. 11, 750789 (2021).","journal-title":"Front. Oncol."},{"key":"44665_CR47","doi-asserted-by":"publisher","first-page":"18439","DOI":"10.1073\/pnas.2009316117","volume":"117","author":"W Ren","year":"2020","unstructured":"Ren, W. et al. Direct readout of heterochromatic H3K9me3 regulates DNMT1-mediated maintenance DNA methylation. Proc. Natl. Acad. Sci. U. S. A. 117, 18439\u201318447 (2020).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"44665_CR48","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.bbagrm.2014.02.007","volume":"1839","author":"NR Rose","year":"2014","unstructured":"Rose, N. R. & Klose, R. J. Understanding the relationship between DNA methylation and histone lysine methylation. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 1839, 1362\u20131372 (2014).","journal-title":"Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms"},{"issue":"9","key":"44665_CR49","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41580-022-00483-w","volume":"23","author":"J Padeken","year":"2022","unstructured":"Padeken, J., Methot, S. P. & Gasser, S. M. Establishment of H3K9-methylated heterochromatin and its functions in tissue differentiation and maintenance. Nat. Rev. Mol. Cell Biol. 23(9), 623\u2013640 (2022).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"44665_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-017-0996-5_3","author":"G Stacey","year":"2001","unstructured":"Stacey, G. & MacDonald, C. Immortalisation of primary cells. Cell Cult. Methods In Vitro Toxicol. https:\/\/doi.org\/10.1007\/978-94-017-0996-5_3 (2001).","journal-title":"Cell Cult. Methods In Vitro Toxicol."},{"key":"44665_CR51","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1093\/nar\/gky224","volume":"46","author":"R Noberini","year":"2018","unstructured":"Noberini, R. et al. Extensive and systematic rewiring of histone post-translational modifications in cancer model systems. Nucleic Acids Res. 46, 3817\u20133832 (2018).","journal-title":"Nucleic Acids Res."},{"key":"44665_CR52","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3390\/cancers15030647","volume":"15","author":"L Provez","year":"2023","unstructured":"Provez, L. et al. Pre-clinical evaluation of the hypomethylating agent Decitabine for the treatment of T-cell lymphoblastic lymphoma. Cancers (Basel) 15, 647 (2023).","journal-title":"Cancers (Basel)"},{"key":"44665_CR53","unstructured":"Satilmis, O. Histon post-translationele modificaties als potenti\u00eble biomarkers voor T-ALL behandeling en hun rol in gepersonaliseerde geneeskunde. (Ghent University, 2022)."},{"key":"44665_CR54","first-page":"e22","volume":"45","author":"W Zhou","year":"2017","unstructured":"Zhou, W., Laird, P. W. & Shen, H. Comprehensive characterization, annotation and innovative use of Infinium DNA methylation BeadChip probes. Nucleic Acids Res. 45, e22\u2013e22 (2017).","journal-title":"Nucleic Acids Res."},{"key":"44665_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/gb-2013-14-9-r105","volume":"14","author":"J Nordlund","year":"2013","unstructured":"Nordlund, J. et al. Genome-wide signatures of differential DNA methylation in pediatric acute lymphoblastic leukemia. Genome Biol. 14, 1\u201315 (2013).","journal-title":"Genome Biol."},{"key":"44665_CR56","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/bioinformatics\/btu049","volume":"30","author":"MJ Aryee","year":"2014","unstructured":"Aryee, M. J. et al. Minfi: A flexible and comprehensive bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics 30, 1363\u20131369 (2014).","journal-title":"Bioinformatics"},{"key":"44665_CR57","doi-asserted-by":"publisher","first-page":"3982","DOI":"10.1093\/bioinformatics\/btx513","volume":"33","author":"Y Tian","year":"2017","unstructured":"Tian, Y. et al. ChAMP: Updated methylation analysis pipeline for Illumina beadchips. Bioinformatics 33, 3982\u20133984 (2017).","journal-title":"Bioinformatics"},{"key":"44665_CR58","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1158\/2643-3230.BCD-20-0059","volume":"1","author":"J Roels","year":"2020","unstructured":"Roels, J. et al. Aging of preleukemic thymocytes drives CpG island hypermethylation in T-cell acute lymphoblastic leukemia. Blood Cancer Discov. 1, 274\u2013289 (2020).","journal-title":"Blood Cancer Discov."},{"key":"44665_CR59","unstructured":"Direct acid extraction. https:\/\/www.protocols.io\/view\/direct-acid-extraction-bp2l6x6odlqe\/v1."},{"key":"44665_CR60","unstructured":"One-dimensional SDS-PAGE (9\u201318% TGX gel). https:\/\/www.protocols.io\/view\/one-dimensional-sds-page-9-18-tgx-gel-5jyl8pz27g2w\/v1."},{"key":"44665_CR61","unstructured":"Propionylation and tryptic digestion. https:\/\/www.protocols.io\/view\/propionylation-and-tryptic-digestion-5jyl8pz36g2w\/v1."},{"key":"44665_CR62","doi-asserted-by":"publisher","first-page":"109813","DOI":"10.1016\/j.envint.2025.109813","volume":"204","author":"TM Michailidis","year":"2025","unstructured":"Michailidis, T. M. et al. Aflatoxin B1 induces subtle but coordinated histone modifications in Epstein-Barr virus infected and non-infected Burkitt lymphoma cells. Environ. Int. 204, 109813 (2025).","journal-title":"Environ. Int."},{"key":"44665_CR63","unstructured":"Wei T, S. V. R package \u2018corrplot\u2019: Visualization of a Correlation Matrix. (Version 0.95). https:\/\/github.com\/taiyun\/corrplot. (2024)."},{"key":"44665_CR64","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon, P. et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498 (2003).","journal-title":"Genome Res."},{"key":"44665_CR65","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkae1011","volume":"53","author":"Y Perez-Riverol","year":"2025","unstructured":"Perez-Riverol, Y. et al. The PRIDE database at 20 years: 2025 update. Nucleic Acids Res. 53, D543\u2013D553 (2025).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44665-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44665-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44665-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:06:51Z","timestamp":1778670411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44665-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["44665"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-44665-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15029"}}